创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the features of the ADCC platform?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-24 14:16
  • Views:

(Summary description)In the field of biomedicine, research targeting tumor immunotherapy has always been at the forefront of scientists' continuous exploration and breakthroughs. Among them, antibody-dependent cytotoxicity (ADCC), as a key process in natural immune response, has high research value and clinical application potential. With its unique ADCC platform, InnoModels Biotechnology provides powerful and comprehensive support for tumor immunotherapy research.

InnoModels Biotechnology: What are the features of the ADCC platform?

(Summary description)In the field of biomedicine, research targeting tumor immunotherapy has always been at the forefront of scientists' continuous exploration and breakthroughs. Among them, antibody-dependent cytotoxicity (ADCC), as a key process in natural immune response, has high research value and clinical application potential. With its unique ADCC platform, InnoModels Biotechnology provides powerful and comprehensive support for tumor immunotherapy research.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-24 14:16
  • Views:
Information

In the field of biomedicine, research targeting tumor immunotherapy has always been at the forefront of scientists' continuous exploration and breakthroughs. Among them, antibody-dependent cytotoxicity (ADCC), as a key process in natural immune response, has high research value and clinical application potential. With its unique ADCC platform, InnoModels Biotechnology provides powerful and comprehensive support for tumor immunotherapy research.
InnoModels' ADCC platform is highly regarded for its precision, efficiency and clinical relevance. By simulating the ADCC process in the human body, the platform is able to deeply explore the interaction mechanism between antibodies and tumor cells, thus providing powerful support for the development of tumor therapeutic drugs.
First of all, the InnoModels Biotechnology ADCC platform shows great flexibility in the selection of cell sources. The platform can either use tumor cell lines for extensive research and testing, or select primary tumor cells for more realistic simulation experiments. This diversified cell source not only meets the needs of researchers for different experimental conditions, but also improves the reliability and accuracy of experimental results.

 


Secondly, InnoModels Biotechnology ADCC platform has high precision and sensitivity in the detection of antibody binding to tumor cells. The platform is able to monitor the binding process of antibodies to tumor cell antigens and the cytotoxic activity of NK cells after activation of Fc receptors in real time through advanced technical means. This precise detection capability enables researchers to gain an in-depth understanding of the details of the ADCC process, which in turn provides key information for optimizing antibody design and improving therapeutic efficacy.
In addition, the InnoModels Biotechnology ADCC platform is highly stable and reproducible. The platform adopts advanced experimental techniques and strict experimental procedures to ensure the stability and reliability of each experimental result. This highly consistent experimental data provides researchers with a reliable reference basis and helps accelerate the development process of tumor immunotherapy drugs.
It is worth mentioning that InnoModels Biotechnology also has a stable domestic platform for humanized mouse models of the immune system (HIS) and a platform for human-derived tumor xenografts (PDX). These platforms, together with the ADCC platform, complement each other and constitute the complete layout of InnoModels Electron's research in the field of tumor immunotherapy. These platforms not only provide researchers with experimental conditions closer to the clinic, but also provide powerful technical support for the development and application of tumor immunotherapy drugs.
In summary, with its precision, high efficiency and closeness to the clinic, InnoModels' ADCC platform has demonstrated strong advantages in the field of tumor immunotherapy research. In the future, with the continuous development and innovation of biopharmaceutical technology, InnoModels Biotechnology will continue to plough into this field and contribute more to the research, development and application of tumor immunotherapy drugs.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司